Last reviewed · How we verify
NCT05351346
Genotype-guided Treatment in DLBCL
Phase 3 trial testing Rituximab in Diffuse Large B Cell Lymphoma in 1,100 participants. Currently enrolling.
1 June 2026
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1,100 |
| Start date | 1 June 2022 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 June 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Rituximab
- Cyclophosphamide (cyclophosphamide) — full drug profile →
- Doxorubicin
- Vincristine
- Prednisone (prednisone) — full drug profile →
- Orelabrutinib
- Lenalidomide — full drug profile →
- Decitabine (decitabine) — full drug profile →
Conditions studied
- Diffuse Large B Cell Lymphoma — all drugs for Diffuse Large B Cell Lymphoma →
Sponsor
Ruijin Hospital
Who can join
Adults 18 to 80, any sex, with Diffuse Large B Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of genotype-guided targeted agents plus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-X) versus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with diffuse large B-cell lymphoma
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
Shen R, Fu D, Dong L, Zhang MC, et al · · 2023 · cited 78× · PMID 37032379 · DOI 10.1038/s41392-023-01358-y -
The current landscape of frontline large B-cell lymphoma trials.
Qualls D, Armand P, Salles G. · · 2025 · cited 14× · PMID 39316716 · DOI 10.1182/blood.2023023789
Verify or expand the search:
- PubMed search for NCT05351346
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rituximab
Trials testing the same drug.
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
- NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
- NCT06965114 — Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia · Phase 1, PHASE2 · recruiting
- NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting
Other recruiting trials for Diffuse Large B Cell Lymphoma
Currently open trials in the same condition.
- NCT06687772 — CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant · Phase 2 · recruiting
- NCT06208735 — CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · Phase 1 · recruiting
- NCT06736613 — A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma · Phase 2 · recruiting
- NCT06552572 — Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy · Phase 2 · active not recruiting
- NCT06550141 — Emapalumab Prevention of CAR-T Cell Associated Toxicities · Phase 2 · recruiting
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05351346 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 24 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05351346.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing